RxDoctor Payments Data

Caitlyn Mitchell

Optometrist · Waterbury, CTNPI 1518221142

Payments from drug & device makers

$2,521in general payments, 2019–2025

Across 109 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$457
  • Sun Pharmaceutical Industries Inc.$274
  • Novartis$268
  • Alcon$237
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$196
  • Oyster Point Pharma, Inc.$152
  • plus $937 from 17 others

What the payments were for

  • Food & beverage$2,509100%
  • Entertainment$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,521 in reported general payments places this provider in the 75th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$79,845
Medicare patients
317
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine114$114,819
XiidraLifitegrast30$48,008
TyrvayaVarenicline Tartrate19$26,599
Cyclosporine48$24,715
LumiganBimatoprost37$21,492
Loteprednol Etabonate78$11,786
RhopressaNetarsudil Mesylate12$4,572
VyzultaLatanoprostene Bunod12$4,320
Tobramycin-DexamethasoneTobramycin/Dexamethasone80$3,761
ErythromycinErythromycin Base299$2,854
Brimonidine Tartrate19$2,638
Timolol Maleate49$1,182
Fluorometholone19$1,079
Prednisolone Acetate29$967
Latanoprost112$896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$117$136,311151 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$53$52,32842 claims
Oyster Point Pharma, Inc.Tyrvaya$152$26,59919 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$196$11,78678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →